C-Reactive Protein In Hospital Patients In A Southwestern Nigerian Community
DOI:
https://doi.org/10.51406/jnset.v9i1.1056Keywords:
c-reactive, significant, patientsAbstract
This study was conducted to evaluate c-reactive proteins on some inflammatory diseases among individuals aged 1 year and above attending out-patient clinic and emergency units of three hospitals in Abeokuta in southwestern Nigeria. Of the 266 blood samples examined overall, the CRP value was highest (16.7%) among age group 31-40 years and there was significant difference between CRP value and age groups (p=0.0060). More males (18%) had high CRP than female (16%), however there was no significant difference between the CRP values and sex. C-reactive protein was significantly high among the patients with anaemia (p<0.0001. r = -0.376). Of the patients with high CRP, all had significantly elevated erythrocyte sedimentation rate (p<0.0001). There was significant difference between CRP and both urea and creatinine (P<0.0001). There was association between CRP and cholesterol with X2 value of 59.484 and significant at less than 1%.
References
Bauer, J.D., Akermann, P.G., Toro, G. 1974. Clinical laboratory methods. 8th Edition. The C.V. Mosby Company, Saint Louis, U.S.A. 393 – 398.
Brigden, M. 1998. The erythrocyte sedimentation rate. Still a helpful test when used judiciously. Postgraduate Medicine, 103: 257 – 274.
Brooks, G., Bulel, J., Morse, S. 1998. In: Jaetz, Melnick and Adelberg (Editors). Medical Microbiology. 21st Ed. Appleton and Lange. Stanford, California, 475 – 476.
Clyne, B., Jonathan, S.O. 2009. The C-reactive protein. Journal of Emergency Medicine, 17: 1019 – 1025.
Cook, N.R., Buring, J.E., Ridker, P.M. 2006. The effect of including C-reactive protein in cardiovascular risk prediction models for women. Annale of International Medicine, 145: 21 – 29.
Coventry, B.J., Ashdown, M.L., Quinn, M.A., Markovic, S.N., Yatomi-Clarke, S.L., Robinson, A.P. 2009. CPR, identifies homeostatic immune oscillations in cancer patients: a potential treatment targeting tool? Journal of Translational Medicine, 102 – 108.
Cushman, M., Arnold, A.M., Psaty, B.M., Manohio, T.A., Kuller, L.H., Burke, G.L. 2005. C-reactive protein and the 10-year incidence of coronary heart disease in older men and women: the cardiovascular health study. Circulation, 112: 25 – 31.
Cushman, M., McClure, L.A., Howard, V.J., Jenny, N.S., Lakoski, S.G., Howard, G. 2009. Implications of Increased C-Reactive Protein for Cardiovascular Risk Stractification in Black and White Men and Women in the U.S. Clinic Chemistry, 55: 1627 – 1636.
Davidsohn, I., Henry, J.B. 1974. Clinical Diagnosis. 15th Ed. W.B. Saunders Company. Philadelphia, U.S.A. 967 – 977.
Gracia-Moll, X., Zouridakis, E., Cole, D. 2000. CRP in patients with stable angina: differences in baseline concentration between men and women. European Heart Journal, 21: 1598 – 1606.
Jaye, D.L., Waites, K.L. 1997. Clinical applications of C-reactive protein in pediatrics. Pediatric Infectious Disease Journal, 16: 735 – 747.
John, D., Wheeler, J.G., Hirschfield, G.M., Eda, S., Eiriksdottir, G., Rumley, A., Lowe, G.D., Pepys, M.B. 2004. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. New England Journal of Medicine, 350: 1387 – 1397.
Kanfer, E.J., Nicol, B.A. 1997 Haemoglobin concentration and erythrocyte sedimentation rate in primary care patients. Journal of the Royal Society of Medicine, 90: 16 – 18.
Lau, B., Sharret, A.R., Kingsley, L.A., Post, W., Palella, F.J., Visscher, B., Gange, S.J. 2006. C-Reactive Protein is a Marker for Human Immunodeficiency Virus Disease Progression. Archter International Medicine, 166: 64 – 70.
Lloyd-Jone, D.M., Liu, K., Tian, L., Greenland, P. 2006. Narrative review: assessment of C-reactive protein in risk prediction for cardiovascular disease. Annale International Medicine, 145: 35 – 42.
McCarty, M. 1947. The occurrence during acute infections of a protein not normally present in the blood. IV. Crystalization of the C-reactive protein. Journal of Experimental Medicine, 85: 491 – 498.
Meier-Ewert, H.K., Ridker, P.M., Rifai, N., Price, N., Dinges, D.F., Mullington, J.M. 2001. Absence of diurnal variation of C-reative protein concentrations in healthy human subjects. Clinical Chemistry, 47: 426 – 430.
Pasceri, V., Willerson, J.T., Yeh, E.T. 2000. Direct proinflammatory effect of C-reactive protein in human epithelial cells. Circulation, 102: 2165 – 2221.
Pepys, M.B., Hirschfield, G.M. 2003. C-reactive protein: a critical update. Journal of Clinical Investigation, 111: 1805 – 1812.
Reingold, J.S., Wanke, C., Kotler, D.P., Lewis, C.E., Tracy, R., Heymsfield, S., Tien,P.C., Bacchetti, P., Scherzer, R., Grunfeld, C., Shlipak, M.G. 2008. Assocaition of HIV infection and HIV/HCV co-infection with C-reactive Protein Levels. Journal of Acquired Immune Deficiency Syndrome, 48: 142 – 148.
Ridker, P.M. 2003. Rosuvastation in primary prevention of cardiovascular disease among patients with low level of low-density lipoprotein cholesterol and elevated high-sensitive C-reactive protein: rationale and design of the JUPITER trial. Circulation, 108: 2292 – 2297.
Ridker, P.M., Hennekens, C.H., Buring, J.E. 2000. C-reactive protein and other makers of inflammation in the prediction of cardiovascular diseases in women. New England Journal of Medicine, 42: 836 – 843.
Ridker, P.M., Rifai, N., Rose, L. 2002. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular event. New England Journal of Medicine, 347: 1557 – 1565.
Ridker, P.M., Cook, N. 2004. Clinical usefulness of very high and very low levels of C-reactive protein across the full range of Famingham Risk Scores. Circulation, 109: 1955 – 1959.
Ridker, P.M., Buring, J.E., Rifai, N., Cook, N.R. 2007. Development and validation of global cardiovascular risk in women. The Reynolds Risk Score. Journal of American Medical Association, 297: 611 – 619.
Roivainen, M., Viik-Kajander, M., Palosuo, T., Toivanen, P., Leinonen, M., Saikku, P. 2000. Infections, inflammation and the risk of coronary heart disease. Circulation, 110: 252 – 257.
Tillett, W.S., Francis, J.T. 1930. Serological reactions in pneumonia with non-protein somatic fraction of Pneumococcus. Journal of Experimental Medicine, 52: 561 – 585.
Zacho, J., Tybjnerg-Hanzen, A., Jensen, J.S., Grande, P., Sillesen, H., Nordestgaard, B.G. 2008. Gentrically elevated C-reactive protein and uschemic vascular disease. New England Journal of Medicine, 359: 1897 – 1908.
Brigden, M. 1998. The erythrocyte sedimentation rate. Still a helpful test when used judiciously. Postgraduate Medicine, 103: 257 – 274.
Brooks, G., Bulel, J., Morse, S. 1998. In: Jaetz, Melnick and Adelberg (Editors). Medical Microbiology. 21st Ed. Appleton and Lange. Stanford, California, 475 – 476.
Clyne, B., Jonathan, S.O. 2009. The C-reactive protein. Journal of Emergency Medicine, 17: 1019 – 1025.
Cook, N.R., Buring, J.E., Ridker, P.M. 2006. The effect of including C-reactive protein in cardiovascular risk prediction models for women. Annale of International Medicine, 145: 21 – 29.
Coventry, B.J., Ashdown, M.L., Quinn, M.A., Markovic, S.N., Yatomi-Clarke, S.L., Robinson, A.P. 2009. CPR, identifies homeostatic immune oscillations in cancer patients: a potential treatment targeting tool? Journal of Translational Medicine, 102 – 108.
Cushman, M., Arnold, A.M., Psaty, B.M., Manohio, T.A., Kuller, L.H., Burke, G.L. 2005. C-reactive protein and the 10-year incidence of coronary heart disease in older men and women: the cardiovascular health study. Circulation, 112: 25 – 31.
Cushman, M., McClure, L.A., Howard, V.J., Jenny, N.S., Lakoski, S.G., Howard, G. 2009. Implications of Increased C-Reactive Protein for Cardiovascular Risk Stractification in Black and White Men and Women in the U.S. Clinic Chemistry, 55: 1627 – 1636.
Davidsohn, I., Henry, J.B. 1974. Clinical Diagnosis. 15th Ed. W.B. Saunders Company. Philadelphia, U.S.A. 967 – 977.
Gracia-Moll, X., Zouridakis, E., Cole, D. 2000. CRP in patients with stable angina: differences in baseline concentration between men and women. European Heart Journal, 21: 1598 – 1606.
Jaye, D.L., Waites, K.L. 1997. Clinical applications of C-reactive protein in pediatrics. Pediatric Infectious Disease Journal, 16: 735 – 747.
John, D., Wheeler, J.G., Hirschfield, G.M., Eda, S., Eiriksdottir, G., Rumley, A., Lowe, G.D., Pepys, M.B. 2004. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. New England Journal of Medicine, 350: 1387 – 1397.
Kanfer, E.J., Nicol, B.A. 1997 Haemoglobin concentration and erythrocyte sedimentation rate in primary care patients. Journal of the Royal Society of Medicine, 90: 16 – 18.
Lau, B., Sharret, A.R., Kingsley, L.A., Post, W., Palella, F.J., Visscher, B., Gange, S.J. 2006. C-Reactive Protein is a Marker for Human Immunodeficiency Virus Disease Progression. Archter International Medicine, 166: 64 – 70.
Lloyd-Jone, D.M., Liu, K., Tian, L., Greenland, P. 2006. Narrative review: assessment of C-reactive protein in risk prediction for cardiovascular disease. Annale International Medicine, 145: 35 – 42.
McCarty, M. 1947. The occurrence during acute infections of a protein not normally present in the blood. IV. Crystalization of the C-reactive protein. Journal of Experimental Medicine, 85: 491 – 498.
Meier-Ewert, H.K., Ridker, P.M., Rifai, N., Price, N., Dinges, D.F., Mullington, J.M. 2001. Absence of diurnal variation of C-reative protein concentrations in healthy human subjects. Clinical Chemistry, 47: 426 – 430.
Pasceri, V., Willerson, J.T., Yeh, E.T. 2000. Direct proinflammatory effect of C-reactive protein in human epithelial cells. Circulation, 102: 2165 – 2221.
Pepys, M.B., Hirschfield, G.M. 2003. C-reactive protein: a critical update. Journal of Clinical Investigation, 111: 1805 – 1812.
Reingold, J.S., Wanke, C., Kotler, D.P., Lewis, C.E., Tracy, R., Heymsfield, S., Tien,P.C., Bacchetti, P., Scherzer, R., Grunfeld, C., Shlipak, M.G. 2008. Assocaition of HIV infection and HIV/HCV co-infection with C-reactive Protein Levels. Journal of Acquired Immune Deficiency Syndrome, 48: 142 – 148.
Ridker, P.M. 2003. Rosuvastation in primary prevention of cardiovascular disease among patients with low level of low-density lipoprotein cholesterol and elevated high-sensitive C-reactive protein: rationale and design of the JUPITER trial. Circulation, 108: 2292 – 2297.
Ridker, P.M., Hennekens, C.H., Buring, J.E. 2000. C-reactive protein and other makers of inflammation in the prediction of cardiovascular diseases in women. New England Journal of Medicine, 42: 836 – 843.
Ridker, P.M., Rifai, N., Rose, L. 2002. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular event. New England Journal of Medicine, 347: 1557 – 1565.
Ridker, P.M., Cook, N. 2004. Clinical usefulness of very high and very low levels of C-reactive protein across the full range of Famingham Risk Scores. Circulation, 109: 1955 – 1959.
Ridker, P.M., Buring, J.E., Rifai, N., Cook, N.R. 2007. Development and validation of global cardiovascular risk in women. The Reynolds Risk Score. Journal of American Medical Association, 297: 611 – 619.
Roivainen, M., Viik-Kajander, M., Palosuo, T., Toivanen, P., Leinonen, M., Saikku, P. 2000. Infections, inflammation and the risk of coronary heart disease. Circulation, 110: 252 – 257.
Tillett, W.S., Francis, J.T. 1930. Serological reactions in pneumonia with non-protein somatic fraction of Pneumococcus. Journal of Experimental Medicine, 52: 561 – 585.
Zacho, J., Tybjnerg-Hanzen, A., Jensen, J.S., Grande, P., Sillesen, H., Nordestgaard, B.G. 2008. Gentrically elevated C-reactive protein and uschemic vascular disease. New England Journal of Medicine, 359: 1897 – 1908.
Downloads
Issue
Section
Articles
